Laboratory diagnosis, treatment and prevention of Rickettsia rickettsii

Laboratory diagnosis of Rickettsia rickettsii

Specimen: Skin biopsies, serum

Direct detection method

  • Although Rickettsiae stain poorly with Gram stain, they can be stained with Giemsa or Gimenez stains.
  • Direct detection of R. rickettsii antigen in skin biopsy specimens of the rash from infected patients by direct fluorescent antibody test using the specific anti-rickettsial antibodies is a rapid and specific method for confirming diagnosis of Rocky Mountain spotted fever.

Laboratory diagnosis, treatment and prevention of Rickettsia rickettsii

Culture

  • R. rickettsii can be isolated in embryonated egg or tissue cultures.
  • However due to associated risk of infection, cultures are rarely attempted.

Serology

  • Definite diagnosis of Rocky Mountain spotted fever is made by employing serological tests that detect R. rickettsii immunoglobulin G (IgG) antibodies.
  • The Weil-Felix test, which is a non specific in nature, considered as an archaic test is still in use in few laboratories.
  • It relies on the agglutination of certain strains of the enteric bacterium Proteus vulgaris, which shares cross-reactive antigens with certain rickettsiae.
  • The serology test that is considered the reference method is the microimmunofluorescence (MIF) test.
  • The test detects antibodies directed against outer membrane proteins (species-specific) and the LPS antigen.
  • The sensitivity and specificity of MIF is high, with diagnostic levels of antibodies generally detected in the second week of illness.
  • Indirect immunofluorescent antibody (IFA) test and enzyme linked immunosorbent assay (ELISA) are new serological tests that are used for early diagnosis of the condition.
  • Demonstration of a fourfold rise in antibody titers between acute and convalescent sera or demonstration of antibody titre of 1:64 or more in a single serum is diagnostic of the disease.
  • These antibodies are detected in the serum 2–3 weeks after the onset of the disease and remain in the serum after a very long period of time.

Molecular diagnosis

  • Detection of rickettsial DNA or Omp genes by PCR is more rapid than isolation and allows specific identification.
  • PCR has been used to detect R. rickettsii DNA in the skin biopsy specimens of the rash with good sensitivity and high specificity.
  • A variety of gene targets are used, including gene sequences for outer membrane proteins (OmpA, OmpB), the 17-kDa lipoprotein, and citrate synthase.

Other testing

  • Leukopenia is present initially, then mild leukocytosis; patients usually have a normal WBC count.
  • Platelets counting may show thrombocytopenia.
  • Sodium levels may be decreased in more severe disease.
  • Alanine​ aminotransferase (ALT) and aspartate aminotransferase (AST) may be slightly elevated.
  • Mild cerebrospinal fluid pleocytosis with monocyte predominance.

Treatment of Rickettsia rickettsii

  • Tetracycline (doxycycline) is the drug of choice.
  • Although the tetracyclines are generally contraindicated for pregnant women and young children, this antibiotic is recommended for all patients with suspected rickettsial disease because it is the most effective antibiotic and inadequately treated disease is associated with a high morbidity and mortality.
  • Chloramphenicol is an alternative choice.
  • Fluoroquinolones, such as ciprofloxacin are effective against R. rickettsii.

Prevention and control of Rickettsia rickettsii

  • The use of protective clothing, insect repellents, avoidance of tick-infested areas, personal hygiene, prompt removal of attached ticks are the best preventive measures against R. rickettsii infection.
  • No vaccine is available against the Rocky Mountain spotted fever.

About Author

Photo of author

Sagar Aryal, PhD

Dr. Sagar Aryal is a microbiologist, researcher, and science communicator from Nepal. He is also co-founder and Research Head of the Department of Natural Products at the Kathmandu Research Institute for Biological Sciences (KRIBS), where he leads research on natural product discovery and microbial biodiversity. Dr. Aryal earned his Ph.D. in Microbiology from Tribhuvan University, Kathmandu, Nepal, in 2025, supported by a DAAD Research Grant and a University Grants Commission (UGC) Nepal Ph.D. Fellowship. His research interests include Actinomycetes, Myxobacteria, microbial taxonomy, and natural products, particularly the discovery of bioactive compounds with potential pharmaceutical applications. He isolated and identified Nocardia nepalensis, a novel bacterial species from Nepal, contributing to understanding microbial diversity in the region. Dr. Aryal has published more than 16 research articles in international journals and contributed three book chapters to established academic publications. He has presented scientific research findings and developed international research collaborations through visits to more than 18 countries across Asia, Europe, North America, and Oceania. From 2023 to 2025, he served as the American Society for Microbiology (ASM) Young Ambassador to Nepal. Since December 2025, he has served as an Editorial Board Member of Scientific Reports, a Nature Portfolio journal. In recognition of his scientific contributions, Dr. Aryal received the NAST Science and Technology Youth Award 2025 from the Nepal Academy of Science and Technology. He previously received the Frs. Locke and Stiller Research Award (LSRA) for the 2017-2018 cycle from St. Xavier's College, Kathmandu, and a Nepal Academy of Science and Technology (NAST) Research Grant for 2017-2018. Alongside his scientific career, Dr. Aryal has more than 15 years of experience in blogging, content writing, and search engine optimization (SEO).